Invasive Candidiasis in Immunocompromised Patients

Clinical Presentation

The hallmark symptoms of invasive candidiasis in immunocompromised patients are nonspecific and include unexplained persistent fever unresponsive to antibacterial therapy, with specific manifestations being rare but critical when present 1, 2
Clinical features are predominantly nonspecific, ranging from unexplained fever to frank sepsis, with the most common presentations including persistent fever despite broad-spectrum antibiotics and signs of sepsis or septic shock without identified bacterial source 1, 2, 3, 4
Unexplained clinical deterioration in the setting of known risk factors is also a common presentation 5

Candidal chorioretinitis occurs in fewer than 15% of candidemic patients but is an absolute indication for antifungal therapy when identified 1, 2
Skin lesions, such as erythematous papular or nodular lesions, occur infrequently 1, 2
Septic arthritis is rare but documented, particularly in immunosuppressed patients 1, 2

Corticosteroids like methylprednisolone are established risk factors for invasive Candida infection by inhibiting cellular immunity, with a dose of 20 mg daily meeting the threshold associated with increased infection risk 6, 1, 2, 7
The combination of rheumatoid arthritis treatment with corticosteroids creates multiple risk factors, including immunosuppression, potential for multi-site Candida colonization, and risk amplified if combined with other immunomodulators 6, 1, 7

The absence of specific symptoms does not exclude invasive candidiasis, and critical errors include waiting for positive blood cultures, dismissing candiduria as colonization, and overlooking colonization patterns 1, 2, 6
Suspect invasive candidiasis if fever persists >4 days despite appropriate antibacterial therapy, and heighten suspicion with evidence of Candida colonization at multiple sites 1, 2
Immediate evaluation is required if any specific manifestation appears, such as eye findings, skin lesions, or joint involvement 1, 2

Consider empiric therapy in septic shock with risk factors, even without confirmed diagnosis, due to the high attributable mortality (30-40%) and the fact that mortality approaches 100% when appropriate antifungal therapy is delayed beyond 24 hours in septic shock 3, 4, 5